Varenicline: no link with cardiovascular events found in meta-analysis

Varenicline (Champix) is a partial agonist to nicotine receptors, and is approved for smoking cessation therapy. However, the FDA has raised concern about a possible increase in the incidence of cardiovascular events of patients taking the drug in randomised trials. In this meta-analysis, Prochaska et al. looked at 22 randomised controlled trials of current tobacco […]

Read More…

Clarifying the role of nicotine in weight control

Despite the impressive gains in cardiovascular morbidity and mortality that have occurred over the past decades, a veritable elephant still exists in the room in the shape of the tidal wave of obesity sweeping the globe, which may reverse these advances.¬† Obesity has proved fundamentally difficult to manage, with few therapies demonstrating sustained weight loss […]

Read More…